Analysis of donor-associated factors in unrelated transplantations of hematopoietic stem cells in children with non-malignant diseases
-
Published:2019-01-22
Issue:4
Volume:5
Page:31-39
-
ISSN:2413-5496
-
Container-title:Russian Journal of Children Hematology and Oncology
-
language:
-
Short-container-title:Ross. ž. det. gematol. onkol.
Author:
Sidorova N. V.1ORCID, Kirgizov K. I.2ORCID, Slinin A. S.3ORCID, Pristanskova E. A.1ORCID, Konstantinova V. V.1ORCID, Burya A. E.1ORCID, Persiantseva M. I.3ORCID, Blagonravova O. L.1ORCID, Skorobogatova E. V.1ORCID
Affiliation:
1. Russian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia 2. Russian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia 3. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Abstract
The choice of the optimal donor in the absence of an HLA-compatible relative, as well as the analysis of the risks of hematopoietic stem cell transplantation (HSCT), is extremely important, especially in patients with non-cancerous diseases. The article analyzes 99 allogeneic HSCTs from unrelated donors in the bone marrow transplantation department of the Russian Children’s Clinical Hospital. The analysis included patients with acquired and congenital forms of non-malignant diseases. The choice of an optimal unrelated donor in the absence of a compatible relative donor, as well as an analysis of the risks of treatment, requires studying the factors that influence the outcome of treatment in this group of patients. It was shown that the level of 2-year overall survival (OS) was 74 % (standard deviation ± 4.7 %). At the same time, clinical manifestations of the acute graft versus host disease of grade I–IV were recorded in 67 % (n = 66) of patients, and severe forms of grade III–IV in 13 % (n = 13) of children. Chronic graft versus host disease (chGVHD) was observed in 29 % (n = 29) patients. When studying the factors associated with the donor, it was found that the differences in the HLA system have a negative effect on the incidence of chGVHD; in a (9/10) HLA-incompatible donor, it was 29 % higher (p = 0.019). Increasing the age of the donor for every 10 years consistently reduces the OS by 9–11 % (p = 0.117), however, the OS with a donor over 46 years old was 100 % (n = 7). No effect on the agents with respect to the following factors with respect to the recipient was found: by sex, blood group, serostatus for cytomegalovirus (CMV). It was noted that the combination of CMV-positive serostatus of the donor and the negative status of the recipient increases the risk of transplant rejection up to 50 % in comparison with other variants of CMV serostatus (p = 0.001). In general, the possibility of performing HSCT from an unrelated donor for patients with non-malignant diseases and possible ways of selecting the optimal donor was noted. Conflict of interest. The authors declare no conflict of interest.Funding. The study was performed without external funding.
Subject
Oncology,Hematology,Pediatrics, Perinatology and Child Health
Reference29 articles.
1. Sevilla J., Fernández-Plaza S., Diaz M.A., Madero L.; Paediatric Disease Working Party of the EBMT. Hematopoietic transplantation for bone marrow failure syndromes and thalassemia. Bone Marrow Transplant 2005;35 Suppl 1:S17–21. doi: 10.1038/sj.bmt.1704838. 2. Storb R., Blume K.G., O’Donnell M.R., Chauncey T., Forman S.J., Deeg H.J., Hu W.W., Appelbaum F.R., Doney K., Flowers M.E., Sanders J., Leisenring W. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantation: the experience in four centers. Biol Blood Marrow Transplant 2001;7(1):39–44. doi: 10.1053/bbmt.2001.v7.pm11215697. 3. Zhou J., Fu Y.W., Liang L.J., Wang Q., Han L.J., Zu Y.L., Zhang Y., Zhu X.H., Yu F.K., Fang B.J., Wei X.D., Song Y.P. A comparative study of unrelated donor and matched-sibling donor allogeneic hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Zhonghua Nei Ke Za Zhi 2016;55(12):927–31. doi: 10.3760/cma.j.issn.0578-1426.2016.12.004. 4. Afanas'ev B.V., Zubarovskaya L.S., Moiseev I.S. Allogennaya transplantatsiya gemopoeticheskikh stvolovykh kletok u detei: nastoyashchee, problemy, perspektivy. Rossiiskii zhurnal detskoi gematologii i onkologii 2015;2(2):28–42. doi: 10.17650/2311-1267-2015-2-2-28-42. [Afanasiev B.V., Zubarovskaya L.S., Moiseev I.S. Allogeneic hematopoietic stem cell transplantation in children: now, problems and prospects. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2015;2(2):28– 42. (In Russ.)]. 5. Passweg J.R., Baldomero H., Bader P., Basak G.W., Bonini C., Duarte R., Dufour C., Kruger N., Kuball J., Lankester A., Montoto S., Nagler A., Snowden J.A., Styczynski J., Mohty M.; European Society for Blood and Marrow Transplantation (EBMT). Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant 2018, Mar 14.
|
|